United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,115,648.40. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Trading Down 1.8%

NASDAQ UTHR opened at $522.83 on Friday. The business’s 50 day moving average is $495.95 and its two-hundred day moving average is $472.65. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $549.50. The stock has a market capitalization of $22.92 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $6.19 EPS. Equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC increased its position in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares in the last quarter. Invesco Ltd. grew its stake in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on UTHR shares. Royal Bank Of Canada raised their target price on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company increased their price target on shares of United Therapeutics from $466.00 to $486.00 and gave the company an “equal weight” rating in a report on Monday, March 23rd. TD Cowen raised their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $549.91.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.